Study of remestemcel-L for treatment of acute respiratory distress syndrome due to COVID-19 fails to meet primary endpoint
A third interim analysis of the trial’s first 180 patients, reported that remestemcel-L, an investigational therapy comprising culture-expanded mesenchymal stem cells, is not likely to meet the primary endpoint of 43% reduction in mortality following 30 days of treatment.
Source:
Biospace Inc.